Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Cagrilintide monotherapy produces about 11.8% reduction at 2.4 mg weekly
Retatrutide needs additional TRIUMPH trial results throughout 2026 before submitting for FDA approval in late 2026 or early 2027, with approval expected in late 2027 and launch in early 2028
Those with weight loss needs accompanied by metabolic syndrome
Anyone under 21 should avoid REGEN unless under medical supervision, as peptide effects on developing bodies are not well studied
US$ 28.00
US$ 29.37
US$ 26.97
US$ 22.11
